| 1 |
Wölflein G, Um IH, Harrison DJ, Arandjelović O. Whole-Slide Images and Patches of Clear Cell Renal Cell Carcinoma Tissue Sections Counterstained with Hoechst 33342, CD3, and CD8 Using Multiple Immunofluorescence. Data 2023;8:40. [DOI: 10.3390/data8020040] [Reference Citation Analysis]
|
| 2 |
Tataru OS, Marchioni M, Crocetto F, Barone B, Lucarelli G, Del Giudice F, Busetto GM, Veccia A, Lo Giudice A, Russo GI, Luzzago S, Piccinelli ML, Vartolomei MD, Musi G, Ferro M. Molecular Imaging Diagnosis of Renal Cancer Using (99m)Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques. Diagnostics (Basel) 2023;13. [PMID: 36832081 DOI: 10.3390/diagnostics13040593] [Reference Citation Analysis]
|
| 3 |
Kuroe T, Watanabe R, Morisue R, Miyazaki S, Kojima M, Murata SC, Nakai T, Taki T, Sakashita S, Sakamoto N, Matsubara N, Masuda H, Ushiku T, Ishii G. Dirty necrosis in renal cell carcinoma is associated with NETosis and systemic inflammation. Cancer Med 2023;12:4557-67. [PMID: 36127822 DOI: 10.1002/cam4.5249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 4 |
Fateh S, Arkawazi L, Tahir S, Rashid R, Rahman D, Aghaways I, Kakamad F, Salih A, Bapir R, Fakhralddin S, Fattah F, Abdalla B, Mohammed S. Renal cell carcinoma T staging: Diagnostic accuracy of preoperative contrast‑enhanced computed tomography. Mol Clin Oncol 2023;18:11. [DOI: 10.3892/mco.2023.2607] [Reference Citation Analysis]
|
| 5 |
He M, Gao Q, Xiang J, Mao Q, Jiang T. Diagnostic Value of Qualitative and Quantitative Contrast-Enhanced Ultrasound for Pathological Subtypes of Small Solid Renal Masses. J Ultrasound Med 2023. [PMID: 36591796 DOI: 10.1002/jum.16169] [Reference Citation Analysis]
|
| 6 |
Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
|
| 7 |
Wolflein G, Um IH, Harrison DJ, Arandjelovic O. HoechstGAN: Virtual Lymphocyte Staining Using Generative Adversarial Networks. 2023 IEEE/CVF Winter Conference on Applications of Computer Vision (WACV) 2023. [DOI: 10.1109/wacv56688.2023.00497] [Reference Citation Analysis]
|
| 8 |
Lin Y, Zhang F, Jin Y, Zhong Q, Tan W, Liu J, Wu Z. NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma. Appl Bionics Biomech 2022;2022:3669296. [PMID: 36606241 DOI: 10.1155/2022/3669296] [Reference Citation Analysis]
|
| 9 |
Gürel A, Baylan B, Özen A, Keleş İ, Öztekin Ü, Demirbaş A, Karalar M, Ulusoy K, Yılmaz M, Erşekerci E, Elmaağaç B, Sulhan H, Doğan AE, Altan M, Keske M, Karadağ MA. Comparison of Renal Cell Cancer Surgery During the COVID-19 Pandemic with Prepandemic Period, Turkey Multicenter Study. uob 2022;21:119-123. [DOI: 10.4274/uob.galenos.2021.2021.11.3] [Reference Citation Analysis]
|
| 10 |
Chen Z, Li Z, Li C, Li B, Wang H, Nong D, Li X, Huang G, Lin J, Li W. Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma. BMC Cancer 2022;22:1277. [PMID: 36474188 DOI: 10.1186/s12885-022-10340-w] [Reference Citation Analysis]
|
| 11 |
Trac N, Oh HS, Jones LI, Caliliw R, Ohtake S, Shuch B, Chung EJ. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. Molecules 2022;27. [PMID: 36500549 DOI: 10.3390/molecules27238457] [Reference Citation Analysis]
|
| 12 |
Zhang X, Zhang G, Xu L, Bai X, Zhang J, Chen L, Lu X, Yu S, Jin Z, Sun H. Prediction of World Health Organization /International Society of Urological Pathology (WHO/ISUP) Pathological Grading of Clear Cell Renal Cell Carcinoma by Dual-Layer Spectral CT. Academic Radiology 2022. [DOI: 10.1016/j.acra.2022.12.002] [Reference Citation Analysis]
|
| 13 |
Di Maida F, Campi R, Grosso AA, Lambertini L, Cadenar A, Giudici S, Pecoraro A, Mari A, Serni S, Minervini A, Belmonte M, Catucci C, Mariottini R, Marzocco A, Moscardi L, Livio V, Mazzola L. Prognostic features of upstaged pT3a renal tumors with fat invasion after robot-assisted partial nephrectomy: is it time for a new subclassification? European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.11.098] [Reference Citation Analysis]
|
| 14 |
De Filippis R, Wölflein G, Um IH, Caie PD, Warren S, White A, Suen E, To E, Arandjelović O, Harrison DJ. Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma. Cancers 2022;14:5387. [DOI: 10.3390/cancers14215387] [Reference Citation Analysis]
|
| 15 |
Zhou C, Ban X, Luo L, Shi C. The value of CT features and demographic data in the differential diagnosis of type 2 papillary renal cell carcinoma from fat-poor angiomyolipoma and oncocytoma. Abdom Radiol (NY) 2022;47:3838-46. [PMID: 36085376 DOI: 10.1007/s00261-022-03644-9] [Reference Citation Analysis]
|
| 16 |
De Filippis R, Wölflein G, Um IH, Caie PD, Warren S, White A, Suen E, To E, Arandjelović O, Harrison DJ. Use of high-plex data reveals novel insights into the tumour microenvironment of clear cell renal cell carcinoma.. [DOI: 10.1101/2022.10.13.22281035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Zschäbitz S, Mikuteit M, Stöhr C, Herrmann E, Polifka I, Agaimy A, Trojan L, Ströbel P, Becker F, Wülfing C, Barth P, Stöckle M, Staehler M, Stief C, Haferkamp A, Hohenfellner M, Duensing S, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Schrader AJ, Hartmann A, Erlmeier F, Steffens S. Expression of nectin-4 in papillary renal cell carcinoma. Discov Oncol 2022;13:90. [PMID: 36136143 DOI: 10.1007/s12672-022-00558-2] [Reference Citation Analysis]
|
| 18 |
Chen Z, Li Z, Li C, Li B, Wang H, Nong D, Li X, Huang G, Lin J, Li W. SPOP could play a potential inhibitory role in human renal cell carcinoma.. [DOI: 10.21203/rs.3.rs-395336/v2] [Reference Citation Analysis]
|
| 19 |
Zhu Z, Zhang C, Qian J, Feng N, Zhu W, Wang Y, Gong Y, Li X, Lin J, Zhou L. Construction and validation of a ferroptosis-related long noncoding RNA signature in clear cell renal cell carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02700-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Abu Haeyeh Y, Ghazal M, El-baz A, Talaat IM. Development and Evaluation of a Novel Deep-Learning-Based Framework for the Classification of Renal Histopathology Images. Bioengineering 2022;9:423. [DOI: 10.3390/bioengineering9090423] [Reference Citation Analysis]
|
| 21 |
Gverović-Antunica A, Puzović V, Fabris Miletić Z, Arapović Slavić D, Šikić M, Kaštelan S. Metamorphopsia as the first clinical sign of renal cell carcinoma. Int J Ophthalmol 2022;15:1407-9. [PMID: 36017043 DOI: 10.18240/ijo.2022.08.27] [Reference Citation Analysis]
|
| 22 |
Jiang H, Zhou X, Zhan X, Li Y, Xiong Y, Long J, Li S, Liu X, Fu B. Clinical study of centrality index in predicting the postoperative pathological nuclear grade of clear cell renal cell carcinoma. Int Urol Nephrol 2022. [PMID: 36030357 DOI: 10.1007/s11255-022-03349-4] [Reference Citation Analysis]
|
| 23 |
Kantarcioğlu Coşkun S. Evaluation of Pathological Prognostic Parameters in Renal Cell Carcinomas: A Single Center Experience. SABD 2022. [DOI: 10.33631/sabd.1138634] [Reference Citation Analysis]
|
| 24 |
Makino T, Kadomoto S, Izumi K, Mizokami A. Epidemiology and Prevention of Renal Cell Carcinoma. Cancers (Basel) 2022;14:4059. [PMID: 36011051 DOI: 10.3390/cancers14164059] [Reference Citation Analysis]
|
| 25 |
Wang Y, Niu X, Wang L, Li Y, Qiao B. Comparison of survival between unilocular cystic and purely solid renal cell carcinoma. Sci Rep 2022;12:12865. [PMID: 35896562 DOI: 10.1038/s41598-022-16856-2] [Reference Citation Analysis]
|
| 26 |
Peng L, Liang J, Wang Q, Chen G. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma. Front Genet 2022;13:798846. [PMID: 35656315 DOI: 10.3389/fgene.2022.798846] [Reference Citation Analysis]
|
| 27 |
Feng C, Lyu Y, Gong L, Wang J. Therapeutic Potential of Natural Products in the Treatment of Renal Cell Carcinoma: A Review. Nutrients 2022;14:2274. [DOI: 10.3390/nu14112274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 28 |
Trevisani F, Floris M, Vago R, Minnei R, Cinque A. Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge? Cells 2022;11:1658. [PMID: 35626699 DOI: 10.3390/cells11101658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Dawsey SJ, Gupta S. Hereditary Renal Cell Carcinoma. KCA 2022. [DOI: 10.3233/kca-210008] [Reference Citation Analysis]
|
| 30 |
Guan Z, Liu S, Luo L, Wu Z, Lu S, Guan Z, Tao K. Identification of Ferroptosis-Related Genes as Biomarkers for Sarcoma. Front Cell Dev Biol 2022;10:847513. [PMID: 35309947 DOI: 10.3389/fcell.2022.847513] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Med 2022. [PMID: 35312175 DOI: 10.1002/cam4.4681] [Reference Citation Analysis]
|
| 32 |
Zhang X, Zhang G, Xu L, Bai X, Lu X, Yu S, Sun H, Jin Z. Utilisation of virtual non-contrast images and virtual mono-energetic images acquired from dual-layer spectral CT for renal cell carcinoma: image quality and radiation dose. Insights Imaging 2022;13. [DOI: 10.1186/s13244-021-01146-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 33 |
Wu T, Yin M, Haleem H. A rare curative case of collecting duct carcinoma. Urol Case Rep 2022;41:101981. [PMID: 34976739 DOI: 10.1016/j.eucr.2021.101981] [Reference Citation Analysis]
|
| 34 |
Mihailović S, Džamić Z, Plješa-ercegovac M. The role of redox homeostasis biomarkers in clear cell renal cell carcinoma development and progression. Medicinski podmladak 2022;73:34-39. [DOI: 10.5937/mp73-35557] [Reference Citation Analysis]
|
| 35 |
Kamli H, Owens EP, Vesey DA, Prasanna R, Li L, Gobe GC, Morais C. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects. Biochem Biophys Res Commun 2022;586:42-8. [PMID: 34826699 DOI: 10.1016/j.bbrc.2021.11.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 36 |
Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
|
| 37 |
Xv Y, Lv F, Guo H, Zhou X, Tan H, Xiao M, Zheng Y. Machine learning-based CT radiomics approach for predicting WHO/ISUP nuclear grade of clear cell renal cell carcinoma: an exploratory and comparative study. Insights Imaging 2021;12:170. [PMID: 34800179 DOI: 10.1186/s13244-021-01107-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 38 |
Demirjian NL, Varghese BA, Cen SY, Hwang DH, Aron M, Siddiqui I, Fields BKK, Lei X, Yap FY, Rivas M, Reddy SS, Zahoor H, Liu DH, Desai M, Rhie SK, Gill IS, Duddalwar V. CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma. Eur Radiol 2021. [PMID: 34757449 DOI: 10.1007/s00330-021-08344-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 39 |
Kubiliūtė R, Žukauskaitė K, Žalimas A, Ulys A, Sabaliauskaitė R, Bakavičius A, Želvys A, Jankevičius F, Jarmalaitė S. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma. J Cancer Res Clin Oncol 2021. [PMID: 34689221 DOI: 10.1007/s00432-021-03837-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Teixeira AL, Patrão AS, Dias F, Silva C, Vieira I, Silva JF, Ferreira M, Morais A, Maurício J, Medeiros R. AGO2 expression levels and related genetic polymorphisms: influence in renal cell progression and aggressive phenotypes. Pharmacogenomics 2021;22:1069-79. [PMID: 34672687 DOI: 10.2217/pgs-2021-0072] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 41 |
Chen XY, Zhang Y, Chen YX, Huang ZQ, Xia XY, Yan YX, Xu MP, Chen W, Wang XL, Chen QL. MRI-Based Grading of Clear Cell Renal Cell Carcinoma Using a Machine Learning Classifier. Front Oncol 2021;11:708655. [PMID: 34660276 DOI: 10.3389/fonc.2021.708655] [Reference Citation Analysis]
|
| 42 |
Liu H, Yang Y. Identification of Mast Cell-Based Molecular Subtypes and a Predictive Signature in Clear Cell Renal Cell Carcinoma. Front Mol Biosci 2021;8:719982. [PMID: 34646862 DOI: 10.3389/fmolb.2021.719982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Canete-Portillo S, Rodriguez Pena MDC, Wang D, Sanchez DF, Netto GJ, Magi-Galluzzi C. Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma. Virchows Arch 2021. [PMID: 34611731 DOI: 10.1007/s00428-021-03214-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 44 |
Al-Shinnag M, Marfan H, Susman R, Wakeling J, Gustafson S, Wood S, Mallett AJ. Birt-Hogg-Dubé Syndrome and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: An Effective Multidisciplinary Approach to Hereditary Renal Cancer Predisposing Syndromes. Front Oncol 2021;11:738822. [PMID: 34604083 DOI: 10.3389/fonc.2021.738822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 45 |
Liu Y, Lv H, Li X, Liu J, Chen S, Chen Y, Jin Y, An R, Yu S, Wang Z. Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway. Int J Biol Sci 2021;17:3522-37. [PMID: 34512163 DOI: 10.7150/ijbs.62114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Ogorevc M, Strikic A, Tomas SZ. Determining the immunohistochemical expression of GLUT1 in renal cell carcinoma using the HSCORE method. Biomed Rep 2021;15:79. [PMID: 34429965 DOI: 10.3892/br.2021.1455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 47 |
Browning L, Colling R, Verrill C. WHO/ISUP grading of clear cell renal cell carcinoma and papillary renal cell carcinoma; validation of grading on the digital pathology platform and perspectives on reproducibility of grade. Diagn Pathol 2021;16:75. [PMID: 34419085 DOI: 10.1186/s13000-021-01130-2] [Reference Citation Analysis]
|
| 48 |
Marko J, Craig R, Nguyen A, Udager AM, Wolfman DJ. Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation. Radiographics 2021;41:1408-19. [PMID: 34388049 DOI: 10.1148/rg.2021200206] [Reference Citation Analysis]
|
| 49 |
Dispagna MA, Daneshvar M, Bratslavsky G. Surgical Insights for the Management of Variant Histology in Renal Cell Carcinoma. Int Braz J Urol 2021;47:935-42. [PMID: 33650834 DOI: 10.1590/S1677-5538.IBJU.2020.0778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:3743. [PMID: 34359645 DOI: 10.3390/cancers13153743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 51 |
Pullen RL Jr. Renal cell carcinoma, part 1. Nursing 2021;51:34-40. [PMID: 34156999 DOI: 10.1097/01.NURSE.0000753972.19135.dc] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 52 |
Tatjana A, Tjota MY, O'Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang P. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch 2021. [PMID: 34128116 DOI: 10.1007/s00428-021-03138-x] [Reference Citation Analysis]
|
| 53 |
Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci 2021;22:6237. [PMID: 34207825 DOI: 10.3390/ijms22126237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 54 |
Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B. Papillary renal cell carcinoma: Review. Urol Oncol 2021;39:327-37. [PMID: 34034966 DOI: 10.1016/j.urolonc.2021.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 55 |
Zhang HM, Wen DG, Wang Y, Bao YG, Yuan Y, Chen YT, Song B. Arterial Spin Labeling MRI for Predicting Microvascular Invasion of T1 Staging Renal Clear Cell Carcinoma Preoperatively. Front Oncol 2021;11:644975. [PMID: 34084743 DOI: 10.3389/fonc.2021.644975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 56 |
Bohosova J, Kubickova A, Slaby O. lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma. Biomolecules 2021;11:664. [PMID: 33947142 DOI: 10.3390/biom11050664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 57 |
Wang X, Lu Y, Tuo Z, Zhou H, Zhang Y, Cao Z, Peng L, Yu D, Bi L. Role of SIRT1/AMPK signaling in the proliferation, migration and invasion of renal cell carcinoma cells. Oncol Rep 2021;45:109. [PMID: 33907836 DOI: 10.3892/or.2021.8060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 58 |
Zhang X, Wang Z, Zeng Z, Shen N, Wang B, Zhang Y, Shen H, Lu W, Wei R, Ma W, Wang C. Bioinformatic analysis identifying FGF1 gene as a new prognostic indicator in clear cell Renal Cell Carcinoma. Cancer Cell Int 2021;21:222. [PMID: 33865387 DOI: 10.1186/s12935-021-01917-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 59 |
Park JS, Jang WS, Kim J, Lee SH, Rha KH, Ham WS. Association between visceral adiposity and DDX11 as a predictor of aggressiveness of small clear-cell renal-cell carcinoma: a prospective clinical trial. Cancer Metab 2021;9:15. [PMID: 33823929 DOI: 10.1186/s40170-021-00251-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 60 |
Zhu M, Ren B, Richards R, Suriawinata M, Tomita N, Hassanpour S. Development and evaluation of a deep neural network for histologic classification of renal cell carcinoma on biopsy and surgical resection slides. Sci Rep 2021;11:7080. [PMID: 33782535 DOI: 10.1038/s41598-021-86540-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 61 |
Zheng Q, Tian G, Xu F, Ci X, Luan R, Wu L, Lu X. The role of Elabela in kidney disease. Int Urol Nephrol 2021;53:1851-7. [PMID: 33683568 DOI: 10.1007/s11255-021-02790-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 62 |
Chen MY, Woodruff MA, Kua B, Rukin NJ. Rapid Segmentation of Renal Tumours to Calculate Volume Using 3D Interpolation. J Digit Imaging 2021;34:351-6. [PMID: 33564999 DOI: 10.1007/s10278-020-00416-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 63 |
Giacosa S, Pillet C, Séraudie I, Guyon L, Wallez Y, Roelants C, Battail C, Evrard B, Chalmel F, Barette C, Soleilhac E, Fauvarque MO, Franquet Q, Sarrazin C, Peilleron N, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O. Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction. Cancers (Basel) 2021;13:576. [PMID: 33540838 DOI: 10.3390/cancers13030576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 64 |
Kuroe T, Watanabe R, Kojima M, Morisue R, Sugano M, Kuwata T, Masuda H, Kusuhara S, Matsubara N, Oda S, Ushiku T, Ishii G. Evaluation of the morphological features and unfavorable prognostic impact of dirty necrosis in renal cell carcinoma. J Cancer Res Clin Oncol 2021;147:1089-100. [PMID: 33475860 DOI: 10.1007/s00432-020-03505-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 65 |
Mou Y, Wu J, Zhang Y, Abdihamid O, Duan C, Li B. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma. BMC Cancer 2021;21:18. [PMID: 33402128 DOI: 10.1186/s12885-020-07726-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 66 |
Nimisha, Singh A, Pandey K. Advanced drug delivery systems in kidney cancer. Advanced Drug Delivery Systems in the Management of Cancer 2021. [DOI: 10.1016/b978-0-323-85503-7.00018-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
Temiz MZ. Commentary: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:730782. [PMID: 34676165 DOI: 10.3389/fonc.2021.730782] [Reference Citation Analysis]
|
| 68 |
Tjota MY, Wanjari P, Segal J, Antic T. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol 2021;115:84-95. [PMID: 33352195 DOI: 10.1016/j.humpath.2020.12.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 69 |
Goldkuhle M, Aldin A, Jakob T, Adams A, Monsef I, Heidenreich A, Dahm P, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013798] [Reference Citation Analysis]
|
| 70 |
Zhu H, Yang B, Dong A, Ye H, Cheng C, Pan G, Zuo C. Dual-Phase 99mTc-MIBI SPECT/CT in the Characterization of Enhancing Solid Renal Tumors: A Single-Institution Study of 147 Cases. Clin Nucl Med 2020;45:765-70. [PMID: 32701813 DOI: 10.1097/RLU.0000000000003212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 71 |
Um IH, Scott-Hayward L, Mackenzie M, Tan PH, Kanesvaran R, Choudhury Y, Caie PD, Tan MH, O'Donnell M, Leung S, Stewart GD, Harrison DJ. Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. J Pathol Inform 2020;11:35. [PMID: 33343995 DOI: 10.4103/jpi.jpi_13_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 72 |
Shan L, Liu W, Zhan Y. Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma. Front Oncol 2020;10:516552. [PMID: 33072561 DOI: 10.3389/fonc.2020.516552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 73 |
Qu LG, Thirugnanasundralingam V, Bolton D, Finelli A, Lawrentschuk N. Tissue-Based Immunohistochemical Markers for Diagnosis and Classification of Renal Cell Carcinoma. Société Internationale d’Urologie Journal 2020;1:68-76. [DOI: 10.48083/mqye9599] [Reference Citation Analysis]
|
| 74 |
Lee S, Jung J, Park I, Park K, Kim DS. A deep learning and similarity-based hierarchical clustering approach for pathological stage prediction of papillary renal cell carcinoma. Comput Struct Biotechnol J 2020;18:2639-46. [PMID: 33033583 DOI: 10.1016/j.csbj.2020.09.029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 75 |
Nahouraii LM, Allen JL, Merrill SB, Lehman E, Kaag MG, Raman JD. Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy. J Kidney Cancer VHL 2020;7:20-5. [PMID: 32953423 DOI: 10.15586/jkcvhl.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Sathianathen NJ, Hwang EC, Coles B, Koziarz A, Vernooij RW, Kang DR, Dahm P. Image-guided percutaneous renal core biopsy of small renal masses to diagnose renal cancer. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013727] [Reference Citation Analysis]
|
| 77 |
Baniak N, Flood TA, Buchanan M, Dal Cin P, Hirsch MS. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology 2020;77:659-66. [PMID: 32639054 DOI: 10.1111/his.14204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 78 |
Zhou J, Zheng S, Zhang Y, Yu Y, Zhou L, Zhang W, Wang C, Shen Q, Yang X. Juxtaglomerular cell tumor: Clinicopathologic evaluation in a large series emphasizing its broad histologic spectrum. Pathol Int 2020;70:844-56. [PMID: 32870578 DOI: 10.1111/pin.13009] [Reference Citation Analysis]
|
| 79 |
Han D, Yu Y, Yu N, Dang S, Wu H, Jialiang R, He T. Prediction models for clear cell renal cell carcinoma ISUP/WHO grade: comparison between CT radiomics and conventional contrast-enhanced CT. Br J Radiol 2020;93:20200131. [PMID: 32706977 DOI: 10.1259/bjr.20200131] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 80 |
Zhang Y, Guan X, Wang H, Wang Y, Yue D, Chen R. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates renal cancer cell migration via cofilin-1. Oncol Lett 2020;20:53. [PMID: 32788940 DOI: 10.3892/ol.2020.11914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 81 |
Simonaggio A, Epaillard N, Elaidi R, Sun CM, Moreira M, Oudard S, Vano YA. [Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer]. Bull Cancer 2020;107:S24-34. [PMID: 32620204 DOI: 10.1016/S0007-4551(20)30275-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 82 |
Ntorkou AA. Editorial for "Multiparametric MRI Radiomic Model for Preoperative Predicting WHO/ISUP Nuclear Grade of Clear Cell Renal Cell Carcinoma". J Magn Reson Imaging 2020;52:1567-8. [PMID: 32592241 DOI: 10.1002/jmri.27267] [Reference Citation Analysis]
|
| 83 |
Singh A, Singh I, Singh N, Puzanov I. Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab. Onco Targets Ther 2020;13:4021-34. [PMID: 32494157 DOI: 10.2147/OTT.S215173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 84 |
Bersanelli M, Brunelli M, Gnetti L, Maestroni U, Buti S. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Ther Adv Med Oncol 2020;12:1758835920915303. [PMID: 32550862 DOI: 10.1177/1758835920915303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 85 |
Kawashima A, Kanazawa T, Kidani Y, Yoshida T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, Ujike T, Nagahara A, Fujita K, Morimoto-Okazawa A, Iwahori K, Uemura M, Imamura R, Ohkura N, Morii E, Sakaguchi S, Wada H, Nonomura N. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Sci Rep 2020;10:6220. [PMID: 32277125 DOI: 10.1038/s41598-020-63060-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 86 |
Yong C, Stewart GD, Frezza C. Immunohistochemistry as a tool for screening rare renal cancers. Ann Transl Med 2019;7:S314. [PMID: 31909051 DOI: 10.21037/atm.2019.10.18] [Reference Citation Analysis]
|
| 87 |
Delecluse S, Zschäbitz S. Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. Onko-Nephrologie 2020. [DOI: 10.1007/978-3-662-59911-2_16] [Reference Citation Analysis]
|
| 88 |
Ciarimboli G, Theil G, Bialek J, Edemir B. Contribution and Expression of Organic Cation Transporters and Aquaporin Water Channels in Renal Cancer. Rev Physiol Biochem Pharmacol 2021;181:81-104. [PMID: 32772272 DOI: 10.1007/112_2020_34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 89 |
Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, Malouf GG. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers (Basel) 2019;12:E99. [PMID: 31906050 DOI: 10.3390/cancers12010099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 90 |
Zastrow S, Krabbe LM, Wolff I, Capitanio U, Klatte T, Ecke T, Huck N, Borgmann H, Scavuzzo A, Cindolo L, Schips L, Surcel C, Mirvald C, Cabo AV, Musquera M, Hutterer G, Prochazkova K, Stief C, Wirth M, May M, Brookman-May S. External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. Int J Clin Oncol 2020;25:145-50. [PMID: 31471787 DOI: 10.1007/s10147-019-01530-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 91 |
Rossi SH, Blick C, Handforth C, Brown JE, Stewart GD; Renal Cancer Gap Analysis Collaborative. Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. Eur Urol Focus 2020;6:991-8. [PMID: 30772357 DOI: 10.1016/j.euf.2019.01.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 92 |
Wu J, Xu WH, Wei Y, Qu YY, Zhang HL, Ye DW. An Integrated Score and Nomogram Combining Clinical and Immunohistochemistry Factors to Predict High ISUP Grade Clear Cell Renal Cell Carcinoma. Front Oncol 2018;8:634. [PMID: 30619768 DOI: 10.3389/fonc.2018.00634] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 93 |
Klatte T, Stewart GD. Renal cell carcinoma: standards and controversies. World J Urol 2018;36:1889-90. [DOI: 10.1007/s00345-018-2490-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
